Literature DB >> 22452676

Probable drug-drug interaction leading to serotonin syndrome in a patient treated with concomitant buspirone and linezolid in the setting of therapeutic hypothermia.

E K Morrison1, A S Rowe.   

Abstract

WHAT IS KNOWN AND
OBJECTIVE: Serotonin syndrome can be a rare but life-threatening condition that is commonly the result of a drug-drug interaction causing excessive serotonin activity. The symptoms associated with serotonin syndrome can include hyperthermia, mental status changes, autonomic hyperactivity and neuromuscular abnormalities, all of which can be concealed in the critically ill patient owing to concomitant therapies. The objective of this case report is to describe a probable drug-drug interaction between buspirone and linezolid, and to highlight the potential confounding effects of hypothermia in this case. CASE
SUMMARY: We present a case of a 28-year-old man who potentially developed serotonin syndrome after coadministration of buspirone and linezolid while being therapeutically cooled for traumatic brain injury. The patient developed hyperthermia, hypertension and tachycardia when buspirone and linezolid were administered concomitantly for 2 days. Symptoms resolved within 24 h after discontinuation of both medications. WHAT IS NEW AND
CONCLUSIONS: Caution should be used in patients receiving multiple serotonergic agents in addition to therapeutic hypothermia. The use of therapeutic hypothermia may mask the symptoms associated with serotonin syndrome, thus delaying the diagnosis and treatment of this potentially deadly condition. If a patient requires the combination of such medications, close monitoring for the symptoms of serotonin syndrome is warranted.
© 2012 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22452676     DOI: 10.1111/j.1365-2710.2012.01344.x

Source DB:  PubMed          Journal:  J Clin Pharm Ther        ISSN: 0269-4727            Impact factor:   2.512


  5 in total

Review 1.  Drug Interactions in Neurocritical Care.

Authors:  Brian Spoelhof; Salia Farrokh; Lucia Rivera-Lara
Journal:  Neurocrit Care       Date:  2017-10       Impact factor: 3.210

2.  Changes in intensity of serotonin syndrome caused by adverse interaction between monoamine oxidase inhibitors and serotonin reuptake blockers.

Authors:  Rui Tao; Mary Rudacille; Gongliang Zhang; Zhiyuan Ma
Journal:  Neuropsychopharmacology       Date:  2014-02-28       Impact factor: 7.853

3.  Characterization of electroencephalographic and biochemical responses at 5-HT promoting drug-induced onset of serotonin syndrome in rats.

Authors:  Zhiyuan Ma; Mary Rudacille; Howard M Prentice; Rui Tao
Journal:  J Neurochem       Date:  2013-01-28       Impact factor: 5.372

4.  Linezolid is associated with serotonin syndrome in a patient receiving amitriptyline, and fentanyl: a case report and review of the literature.

Authors:  Lampros Samartzis; Paraskevi Savvari; Sofoklis Kontogiannis; Stavros Dimopoulos
Journal:  Case Rep Psychiatry       Date:  2013-03-04

5.  Linezolid-induced near-fatal serotonin syndrome during escitalopram therapy: case report and review of literature.

Authors:  Ranganath R Kulkarni; Pratibha R Kulkarni
Journal:  Indian J Psychol Med       Date:  2013-10
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.